InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,852.23
(
0.64%
)
US TECH 100
19,844.40
(
0.56%
)
Dow Jones
43,013.76
(
0.35%
)
Brent Oil
77.03
(
-0.57%
)
Bitcoin
65,892.75
(
4.84%
)
Post# of 253361
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120563
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 74291

Wednesday, 04/22/2009 6:06:43 AM

Wednesday, April 22, 2009 6:06:43 AM

Post# of 253361
JNJ will almost certainly be able to extract some value by challenging the “reverse merger” structure of the MRK-SGP deal, which is an attempt by MRK and SGP to circumvent the change-of-control provisions in SGP’s agreement with JNJ covering the ex-US commercial rights to Remicade and Simponi. I base this assertion on the following:

• The reverse merger is a sham insofar as MRK (not SGP) is clearly the surviving entity in terms of management and BoD composition. Thus, JNJ has a strong case from a legal standpoint, IMO.

• From a practical standpoint, it makes more sense for MRK to give JNJ a modest percentage of SGP’s ex-US rights to Remicade and Simponi (or a lump-sum payment in lieu of such a %) rather than spend a lot of money on legal fees.

• All three companies declined to comment on this matter during their 1Q09 CC’s.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up